Abstract 1042P
Background
Stratum C of the INSIGHT platform trial evaluates eftilagimod alpha (efti) combined with standard of care (SOC) 1st line chemo-immunotherapy (IC) in metastatic NSCLC patients (pts). Efti is an MHC class II agonist (soluble LAG-3 protein) activating antigen-presenting cells followed by T-cell (CD4/CD8) activation. Efti aims to enhance efficacy of IC.
Methods
Pts with 1st line advanced or metastatic NSCLC adenocarcinomas (non-squamous) receive carboplatin AUC5 / pemetrexed 500 mg/m2 q3w 4 cycles followed by optional pemetrexed 500 mg/m2 q3w maintenance plus pembrolizumab 200 mg q3w combined with s.c. efti (30 mg) (q2w for 24 weeks; thereafter q3w till week 52). Imaging: q8w. Primary endpoint: feasibility (safety / tolerability). Secondary endpoints include ORR (RECIST 1.1.), PFS, OS.
Results
From 02Aug2021 till data cut off 18Apr2023 21 pts were enrolled and received treatment (median age: 65 years; 66.7% male). No occurrence of unacceptable toxicities. 10 SAE (grade 1-2: 3; grade 3: 4; grade 4: 0; grade 5: 3) were reported. 1 pancreatitis was possibly related to efti (or immunotherapy in general) and unexpected. So far, 4 pts completed max. treatment with efti for 52 weeks. The most frequent AEs were anemia in 18 pts (52.4%, grade 1-2 and 33.3%, grade 3), neutropenia in 18 pts (19.0%, grade 2 and 66.7%, grade 3-4), leukopenia in 16 pts (28.6%, grade 1-2 and 47.6%, grade 3-4) and thrombocytopenia in 14 pts (42.9%, grade 1-2 and 23.8%, grade 3-4). 5 AEs with grade 3 and no AE with grade 4 and 5 were considered related to efti. Out of 21 pts, 14 pts (67%) showed partial response, 5 (24%) stable disease, 2 (9%) progressive disease as BOR. Even pts with negative or low PD-L1 status (TPS) showed promising efficacy signals. Median follow up: 8.3 months, median OS: not reached.
Conclusions
To date, 30 mg efti combined with SOC appears to be feasible and safe with promising signals of efficacy, so that the trial was amended for inclusion of further 30 pts.
Clinical trial identification
EudraCT 2016-002309-20, NCT03252938.
Editorial acknowledgement
Legal entity responsible for the study
Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, Steinbacher Hohl 2-26, D-60488 Frankfurt, Germany.
Funding
Immutep GmbH.
Disclosure
S. Al-Batran: Financial Interests, Personal, Advisory Board: Lilly, Bristol Myers Squibb, MacroGenics, Immutep, MSD Sharp & Dohme; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Lilly, AIO Studien gGmbH, MCI Deutschland GmbH; Financial Interests, Personal, Other, CEO/founder: Institute of Clinical Cancer Research IKF at Northwest Hospital; Financial Interests, Institutional, Research Grant: Sanofi, Roche, Celgene, Vifor, Medac, Hospira, Lilly, Eurozyto, Immutep, Ipsen, Bristol Myers Squibb, MSD Sharp & Dohme, AstraZeneca, German Cancer Aid (Krebshilfe), German Research Foundation, Federal Ministry of Education and Research. T.O. Goetze: Financial Interests, Personal, Advisory Role: Lilly, MSD Oncology, Bayer, SERVIER, Roche, Novartis, Incyte, Foundation Medicine, Bristol Myers Squibb; Financial Interests, Personal, Speaker’s Bureau: Lilly; Financial Interests, Personal, Research Funding: Deutsche Forschungsgemeinschaft, Gemeinsamer Bundesausschuss; Financial Interests, Institutional, Research Funding: Deutsche Krebshilfe, Lilly, AstraZeneca, Incyte. All other authors have declared no conflicts of interest.
Resources from the same session
1333P - A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
Presenter: Min Hee Hong
Session: Poster session 19
1334P - Activity of first line immunotherapy or chemo-immunotherapy in advanced NSCLC with SMARCA4 deficiency
Presenter: Alina Grecea
Session: Poster session 19
1335P - Phase Ib study to evaluate the safety and tolerability of osimertinib with ipilimumab in EGFRm NSCLC
Presenter: Sonam Puri
Session: Poster session 19
1336P - Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy
Presenter: Felix Saalfeld
Session: Poster session 19
1337P - Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
Presenter: Lin Wu
Session: Poster session 19
1338P - Cerebrospinal fluid pharmacokinetic study of lazertinib and pemetrexed in patients with EGFR-mutant non-small cell lung cancer with leptomeningeal metastases: KCSG21-01 LAZARUS trial
Presenter: Bhumsuk Keam
Session: Poster session 19
1339P - Real-world experience of dacomitinib in mEGFR Advanced NSCLC: A single centre experience
Presenter: Bivas Biswas
Session: Poster session 19
1340P - Propensity score matching analysis for osimertinib versus comparator first-generation EGFR tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non–small cell lung cancer: A Chinese, multicenter, real-world cohort study
Presenter: Dongming Zhang
Session: Poster session 19
1341P - Real-world molecular testing, treatment patterns and clinical outcomes in Chinese advanced NSCLC patients, who have progressed on first-line EGFR-TKI therapy (PISCES)
Presenter: Panwen Tian
Session: Poster session 19
1342P - Effect of the timing of intervention in craniocerebral radiotherapy on prognosis of patients with EGFR-mutant lung adenocarcinoma with brain metastasis
Presenter: Guangchuan Deng
Session: Poster session 19